Disease · MONDO_0018364
malignant epithelial tumor of ovary
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. malignant epithelial tumor of ovary. Diseases, record MONDO_0018364. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018364
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
epithelial cancer of ovary, malignant ovarian epithelial tumor, malignant ovarian epithelial tumour, malignant ovarian surface epithelial-stromal neoplasm, malignant ovarian surface epithelial-stromal tumor, malignant ovarian surface epithelial-stromal tumour, ovarian epithelial cancer, ovarian epithelial tumor, malignant, ovarian malignant epithelial tumor, ovarian malignant epithelial tumour, ovarian stromal cancer
- Open Targets
Drugs229
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| MIRVETUXIMAB SORAVTANSINE | CHEMBL3545132 | Antibody drug conjugate | Approval | FDA | 4 | 3 | 3 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 121 | 121 | 121 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 3 | ClinicalTrials.gov | 110 | 110 | 110 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 3 | ClinicalTrials.gov | 42 | 42 | 42 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 32 | 32 | 32 | Drugs and targets |
| DOXORUBICIN | CHEMBL53463 | Small molecule | Phase 3 | ClinicalTrials.gov | 28 | 28 | 26 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 21 | 21 | 21 | Drugs and targets |
| DOCETAXEL | CHEMBL3545252 | Small molecule | Phase 3 | ClinicalTrials.gov | 20 | 20 | 20 | Drugs and targets |
| GEMCITABINE | CHEMBL888 | Small molecule | Phase 3 | ClinicalTrials.gov | 15 | 15 | 15 | Drugs and targets |
| OLAPARIB | CHEMBL521686 | Small molecule | Phase 3 | ClinicalTrials.gov | 15 | 15 | 15 | Drugs and targets |
1 to 10 of 229
See all 229 drugsTargets248
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| KDR | Vascular endothelial growth factor receptor | 18 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 13 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 13 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 12 | Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 12 | Stem cell growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| TUBA1A | Tubulin | 10 | Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser | Approval | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 10 | Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser | Approval | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 10 | Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser | Approval | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 10 | Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser | Approval | https://conductscience.org/library/genes/7278 | Drugs and targets |
| TUBA3E | Tubulin | 10 | Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser | Approval | https://conductscience.org/library/genes/112714 | Drugs and targets |
1 to 10 of 248
See all 248 targetsTrials385
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 13 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00011986 | Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer | Phase 3 | 4,312 | 2016-04-19 | Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer | CARBOPLATIN, DOXORUBICIN HYDROCHLORIDE, GEMCITABINE, PACLITAXEL, TOPOTECAN HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00262847 | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | Phase 3 | 1,873 | 2013-09-18 | Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma | BEVACIZUMAB, CARBOPLATIN, PACLITAXEL | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00951496 | Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Phase 3 | 1,560 | 2018-05-18 | Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Stage II Fallopian Tube Cancer AJCC v6 and v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7 | BEVACIZUMAB, CARBOPLATIN, CISPLATIN, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT03740165 | Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) | Phase 3 | 1,367 | 2025-09-12 | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms | OLAPARIB, PEMBROLIZUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01015118 | LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer | Phase 3 | 1,366 | 2015-01-15 | Ovarian Neoplasms, Peritoneal Neoplasms | CARBOPLATIN, NINTEDANIB, PACLITAXEL | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00108745 | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer | Phase 3 | 1,157 | 2021-04-01 | Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7 | PACLITAXEL, PACLITAXEL POLIGLUMEX | Its record names the disease | ClinicalTrials.gov |
| NCT00565851 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | Phase 3 | 1,052 | 2020-12-14 | Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Mucinous Adenocarcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinofibroma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Carcinoma | BEVACIZUMAB, CARBOPLATIN, DOCETAXEL, GEMCITABINE HYDROCHLORIDE, PACLITAXEL | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01239732 | A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer | Phase 3 | 1,021 | 2016-06-10 | Ovarian Cancer | BEVACIZUMAB, CARBOPLATIN, PACLITAXEL | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02718417 | Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) | Phase 3 | 998 | 2019-12-18 | Ovarian Cancer | AVELUMAB, CARBOPLATIN, PACLITAXEL | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00866697 | Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Phase 3 | 940 | 2013-12-19 | Ovarian Cancer | PAZOPANIB | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 385
See all 385 trialsComparisons in its trials50
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Nintedanib vs Placebo: serious adverse events | 379 of 902 | 157 of 450 | 1,352 | NCT01015118 | Trial comparisons |
| Pazopanib vs Placebo: deaths from any cause | 3 of 477 | 0 of 461 | 938 | NCT00866697 | Trial comparisons |
| Pazopanib vs Placebo: serious adverse events | 121 of 477 | 51 of 461 | 938 | NCT00866697 | Trial comparisons |
| Arm I (Adjuvant Chemotherapy Suboptimally Debulked) vs Arm II (Neoadjuvant Chemotherapy): serious adverse events | 122 of 346 | 167 of 346 | 692 | NCT01167712 | Trial comparisons |
| Trabectedin + DOXIL vs DOXIL: deaths from any cause | 132 of 286 | 131 of 282 | 568 | NCT01846611 | Trial comparisons |
| Trabectedin + DOXIL vs DOXIL: serious adverse events | 118 of 286 | 58 of 282 | 568 | NCT01846611 | Trial comparisons |
| Sorafenib (Nexavar, BAY43-9006) vs Placebo: serious adverse events | 26 of 123 | 25 of 123 | 246 | NCT00791778 | Trial comparisons |
| Everolimus (RAD001) Plus Bevacizumab vs Placebo Plus Bevacizumab: Incidence of Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) | 43 of 75 | 20 of 75 | 150 | NCT00886691 | Trial comparisons |
| Everolimus (RAD001) Plus Bevacizumab vs Placebo Plus Bevacizumab: serious adverse events | 35 of 75 | 24 of 75 | 150 | NCT00886691 | Trial comparisons |
| Gemcitabine vs Gemcitabine + Pazopanib: Number of Participants With Adverse Events | 73 of 73 | 75 of 75 | 148 | NCT01610206 | Trial comparisons |
1 to 10 of 50
See all 50 comparisons in its trialsPapers from its trials193
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018364
GET https://conductscience.org/api/diseases/v1/MONDO_0018364/drugs?page=2